Alnylam Pharmace. buy StockNews.com
Start price
06.05.23
/
50%
€193.40
Target price
06.05.24
-
Performance (%)
-26.81%
End price
07.05.24
€141.55
Summary
This prediction ended on 07.05.24 with a price of €141.55. The prediction for Alnylam Pharmace. disappointed with a performance of -26.81%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 0.207% | 0.207% | 49.978% |
| iShares Core DAX® | 0.794% | 2.841% | 22.630% |
| iShares Nasdaq 100 | 0.016% | -0.939% | 6.943% |
| iShares Nikkei 225® | 0.309% | -0.648% | 13.619% |
| iShares S&P 500 | 0.181% | -0.442% | 4.692% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten